Ion-682884-cs3
WebEplontersen (ION-682884), a ligand-conjugated antisense oligonucleotide designed to degrade hepatic TTR mRNA, is being evaluated for the treatment of ATTRv amyloidosis with polyneuropathy... WebIONIS ION-682884-CS3 [Neuro] TTRansform This is a phase 3 global, open-label, randomized study to evaluate the efficacy and safety of ION-682884 in patients with hereditary transthyretin-mediated amyloid polyneuropathy. Sponsor: Ionis Site-PI: Distad, sub-I: Preston Contact: Aliya Shabbir ( [email protected])
Ion-682884-cs3
Did you know?
WebDesign and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy — Mayo Clinic
WebInclusion Criteria: Satisfactory completion of ION-682884-CS3 (NCT04136184) (Index Study) as judged by the Investigator and Sponsor, or diagnosis of hATTR-PN and satisfactory completion of either study ISIS 420915-CS101 or study 2024-P001436 (NCT03702829) (both are Investigator-Sponsored studies with inotersen – the … Web27 mrt. 2024 · Coelho T, et al. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Neurol Ther. 2024 Jun;10 (1):375-389. Corporate and financial
Web23 okt. 2024 · Coelho T, Ando Y, Benson MD, Berk JL, Waddington-Cruz M, Dyck PJ, Gillmore JD, Khella SL, Litchy WJ, Obici L, Monteiro C, Tai LJ, Viney NJ, Buchele G, Brambatti M, Jung SW, St L O'Dea L, Tsimikas S, Schneider E, Geary RS, Monia BP, Gertz M. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense … Web10 mrt. 2024 · A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants The safety and scientific validity of this study is the responsibility of the study …
Web17 jul. 2024 · NEURO-TTRansform: a study to evaluate the efficacy and safety of eplontersen (formerly known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in participants with hereditary transthyretin-mediated amyloid polyneuropathy (NCT04136184). ClinicalTrials.gov. Updated June 10, 2024. Accessed July 17, 2024. 11.
Web8 okt. 2024 · 1 Effectiveness 2 Safety Daratumumab for Amyloidosis 18+ All Sexes Duarte, CA This trial is testing a new cancer treatment to see if it is safe for people with heart problems. The new treatment is a combination of drugs, and the trial will also look at how well it works in people of different racial and ethnic backgrounds. Phase 2 Recruiting tsi at accWeb23 okt. 2024 · CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in … tsi assesment college of the mainlandWeb1. Satisfactory completion of ION-682884-CS3 as judged by the Investigator and Sponsor, OR diagnosis of hATTR-PN and satisfactory completion of either study ISIS 420915-CS101 or study 2024-P001436 (both are Investigator-Sponsored studies with inotersen - the unconjugated version of ION-682884) as judged by the Investigator and Sponsor 2. phil vickery gluten free christmas cakeWeb26 feb. 2024 · AKCEA-TTR-L Rx (ION-682884) is a ligand-conjugated antisense (LICA) drug designed for preferential delivery to hepatocytes, the primary source of systemically … tsia swallowing the fishWeb2 nov. 2024 · Participants received ION-682884 matching placebo, subcutaneously (SC) once every 4 weeks [Q4W] (total of 4 doses) along with daily oral supplemental doses of … phil vickery good morning recipes todayWebStudy Name: ION-682884-CS2 (Amyloid) Study Objective: A Phase 3 Global, Double-Blind, Randomized, Placebo‑Controlled. Study to Evaluate the Efficacy and Safety of ION … tsia swallow the fishWeb13 nov. 2024 · ION-682884-CS2 (EudraCT No: 2024-002835-27) is a Phase 3 global, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of AKCEA-TTR-L Rx (ION-682884) in hATTR-CM or wtATTR-CM patients receiving available background standard of care (SoC) therapy. tsia scores texas